Evidence map›Paper›PMID 34974317›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2022

Analysis of sodium 2-mercaptoethane sulfonate in rat plasma using high performance liquid chromatography tandem-mass spectrometry.

Abigail B Donkor, Carl W White, Heidi J Nick, Brian A Logue

Abstract read
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Mesna Improves Outcomes of Sulfur Mustard Inhalation Toxicity in an Acute Rat Model.The Journal of pharmacology and experimental therapeutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abigail B DonkorDepartment of Chemistry and Biochemistry, South Dakota State University, Box 2202, Brookings, South Dakota 57007, USA.
Carl W WhiteDepartment of Pediatrics-Pulmonary and Sleep Medicine Section, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Heidi J NickDepartment of Pediatrics-Pulmonary and Sleep Medicine Section, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Brian A LogueDepartment of Chemistry and Biochemistry, South Dakota State University, Box 2202, Brookings, South Dakota 57007, USA. Electronic address: brian.logue@sdstate.edu.

Funding

Photonics Monitoring and Modeling CoreU54ES027698 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI WHITE, CARL W · 2016 to 2021
$16.7M
NIEHS NIH HHS U54 ES027698
6 · The paper itself

Abstract

Sodium 2-mercaptoethane sulfonate (MESNA) is a thiol-containing compound that has proven to be effective in inactivating acrolein, the toxic metabolite of some anti-cancer drugs (e.g., cyclophosphamide and ifosphamide). Also, it scavenges free radicals which cause numerous disorders by attacking biological molecules. Current methods available to analyze MESNA in biological matrices include colorimetry and high-performance liquid chromatography (HPLC) with ultraviolet, fluorescence, or electrochemical detection. These methods have several limitations including low sensitivity, poor selectivity, a high degree of difficulty, and long analysis times. Hence, a rapid, simple, and sensitive HPLC tandem mass spectrometry (MS/MS) method was developed and validated to quantify MESNA in rat plasma following IP administration. The analysis of MESNA was accomplished via plasma protein precipitation, centrifugation, supernatant evaporation, reconstitution, and HPLC-MS/MS analysis. The method showcases an outstanding limit of detection (20 nM), excellent linearity (R

Indexed as

AnimalsChromatography, High Pressure LiquidDrug StabilityLimit of DetectionLinear ModelsMaleMesnaRatsRats, Sprague-DawleyReproducibility of ResultsTandem Mass SpectrometryMesnaAntineoplasticChemoprotectantFree radicalLC-MS/MSMethod development

Identifiers

PMID34974317
PMCPMC8792353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.